EVIDERA, INC.
BETHESDA, MD

Evidera, Inc., which is part of Pharmaceutical Product Development, LLC (PPD), stands out as the go-to provider for evidence-based solutions focused on assessing and proving real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products. Since its establishment in 2013 and integration into PPD by 2016, Evidera has carved a niche within the global contract research organization landscape. Their mission is to optimize market access and commercial potential from the early development phases through the post-exclusivity era. While based in Bethesda, Florida, with historical ties to Waltham, Massachusetts, Evidera’s influence is truly worldwide, reaching into 38 countries. This international presence allows them to leverage not just scientific expertise but also extensive global operational capabilities. Their work empowers biopharma companies in demonstrating value across various initiatives. Evidera’s team is a vibrant mix of veteran leaders and fresh talent, all geared up with proactive attitudes and deep industry insights. This diversity fosters creativity in interacting with patient advocacy groups and refining study designs through enhanced outreach strategies. A particularly significant highlight is Evidera’s impact on health economic decisions globally, like assisting the National Institute for Health and Care Excellence (NICE) in modifying reimbursement plans for complex treatments such as metastatic castration-resistant prostate cancer (mCRPC). Their work has also been crucial in expediting patient treatment programs around the world. For inquiries or potential collaborations, Evidera’s offices are reachable through several contact numbers. Leading the charge is Kelly McGinnis, Director of Evidera, with key support from Henry Geroek and James Bruni as Assistants. The company was officially incorporated in Florida under file number F16000003503, cementing its status since August 5, 2016.